Healthcare • Biotechnology
EODHD (TTM) · as of Oct 13, 2026
End-of-day close from stored market data, not a live quote.
Sign in to see your position size
We’ll show you if GYRE is in your portfolio and how much it contributes.
Sign inLoading market dates
No upcoming ex-dividend date announced
No 8-K filings in the last 30 days.
4 top institutions tracked
Sentiment: unknown
No recent insider trades detected.
Red flags: 17
59 filers reported a long position in GYRE for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
| Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|
| BlackRock, Inc. | $6.6M | 993.9K | +31% |
| Octagon Capital Advisors LP | $6.3M | 954.4K | New |
| VANGUARD CAPITAL MANAGEMENT LLC | $5.8M | 876.9K | -10.9% |
| GEODE CAPITAL MANAGEMENT, LLC | $3.5M | 533K | +23.5% |
| STATE STREET CORP | $1.6M | 245.4K | +13.4% |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $1.2M | 184.3K | +11.5% |
| NORTHERN TRUST CORP | $1.1M | 169.5K | +26.7% |
| SBI Securities Co., Ltd. | $1.1M | 166.8K | -2.4% |
| VANGUARD FIDUCIARY TRUST CO | $995.6K | 151.1K | +9.7% |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $816.9K | 124K | +77.5% |
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.